

AMENDMENT TO THE SPECIFICATION

Please insert the following paragraphs on page 5, after line 23, of the application as originally filed (i.e., after paragraph [0028] of the application as published, U.S. Pat. Pub. No. 2006/0198785):

-- BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts a chelating agent of one embodiment of the present disclosure with the possible positions of biomolecules being shown;

Fig. 2 depicts five embodiments of bifunctional tridentate pyrazolyl-containing ligands according to the present disclosure;

Fig. 3 is a schematic of a synthesis route for producing 2-[2-(pyrazol-1-yl)ethylimino]ethylamine ($\text{pz}(\text{CH}_2)_2\text{NH}(\text{CH}_2)_2\text{NH}_2$), $\text{pz}(\text{CH}_2)_2\text{N}[(\text{CH}_2)_3\text{COOH}](\text{CH}_2)_2\text{NH}_2$ and (4-carboxylic) $\text{pz}(\text{CH}_2)_2\text{NH}(\text{CH}_2)_2\text{NH}_2$ according to Examples 1-3;

Fig. 4 is a schematic of a synthesis route for producing 3,5-Mepz(CH_2)₂N[(CH_2)₃GlyGlyOEt)](CH_2)₂NH₂ according to Example 4;

Fig. 5 is a schematic of a synthesis route for producing 3,5-Mepz(CH_2)₂S(CH_2)₂S(CH_2)COOEt according to Example 5;

Fig. 6 is a schematic of various Re and Tc complexes produced according to Example 6;

Fig. 7 is a schematic of a synthesis route for producing pyrazolyl-aminophosphines according to Example 7; and

Fig. 8 is a schematic of a synthesis route for producing pyrazolyl-thioetherphosphines according to Example 8. --